M·CAM | News & Events

21795

paged,page-template,page-template-blog-animated,page-template-blog-animated-php,page,page-id-21795,paged-9,page-paged-9,ajax_fade,page_not_loaded,,select-theme-ver-4.1,wpb-js-composer js-comp-ver-7.9,vc_responsive

News & Events Archive

Melbourne PolyTechnic will use tools developed by Executive Director of Innovation and Transformation Dr. David Martin to plan out a thriving workforce

October 18, 2016

M·CAM Founder featured on Business News Australia

October 13, 2016

Should the government be blamed for EpiPen price hike?

August 26, 2016

Catch M·CAM’s owner Dr. David Martin on CNBC’s Closing Bell Aug 26th

August 26, 2016

Dr. David Martin identifies critical failings by the US Patent and Trademark Office and the Food and Drug Administration on the EpiPen case in this clip from CNBC today.

August 26, 2016

Op-Ed: The real EpiPen scandal we should be talking about

August 25, 2016

CNBC picks up M-CAM owner’s blog post as commentary to EpiPen Scandal

August 25, 2016

M·CAM Client eSurface Licensing Deal with FTG Announced

June 29, 2016

News & Events Archive

The CNBC index that finds hidden value in stocks

Behind the rebalancing of the iQ100

Valuing intellectual property

A strategy that avoids Google and Facebook, but is still whipping S&P

CNBC IQ 100 Index highs for the day

Record day for the CNBC IQ 100 Index

CNBC IQ 100 Index continues to soar

All-time and multi-year highs in the CNBC IQ 100

Four IQ 100 Index members hitting highs

CNBC IQ 100 Index is up 37%

CNBC launches a new index to find hidden value in stocks

David Martin: We value companies who know how to use innovation

Putting a price tag on intelligence

Why Facebook and Google are not in CNBC’s new stock index

Valuing intellectual property

David Martin: Defining innovation by the numbers

Unveiling the CNBC IQ 100 Index

Melbourne PolyTechnic will use tools developed by Executive Director of Innovation and Transformation Dr. David Martin to plan out a thriving workforce

M·CAM Founder featured on Business News Australia

Should the government be blamed for EpiPen price hike?

Catch M·CAM’s owner Dr. David Martin on CNBC’s Closing Bell Aug 26th

Dr. David Martin identifies critical failings by the US Patent and Trademark Office and the Food and Drug Administration on the EpiPen case in this clip from CNBC today.

Op-Ed: The real EpiPen scandal we should be talking about

CNBC picks up M-CAM owner’s blog post as commentary to EpiPen Scandal

M·CAM Client eSurface Licensing Deal with FTG Announced